Health care stocks are trading higher Monday following President Trump’s drug pricing speech on Friday afternoon. Call it a relief rally. Or, the Trump bump.
The snap judgment from Wall Street is that Trump’s proposals to rein in drug prices will have a limited impact on biotech and pharmaceuticals companies. But will this be the D.C. “clearing event” that sparks a deeper and sustainable rally in biotech and drug stocks?
About the Author Reprints
